Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
TARAthis companyProtara Therapeutics, Inc.	$2.49	-3.98×	1.16×	0×	-3.19×	-57.1%	0.0%	0.0%	0.0%	-29.2%	-32.3%	-24.7%	0.02×	0.81×	0×	14.58×	0.0%	1	2.7	2	B-
CDXSCodexis, Inc.	$1.13	-3.26×	2.81×	2.02×	-4.86×	-459.7%	86.7%	-54.5%	-62.5%	-87.0%	-30.6%	-16.8%	1.45×	-0.66×	-7.96×	3.82×	0.0%	3	-6.21	1	D+
IVVDInvivyd, Inc.	$0.58	-8.23×	1.76×	7.96×	-3.99×	1722.3%	93.0%	-104.0%	-98.2%	-21.7%	-22.8%	-13.7%	0.01×	4.45×	0×	7.24×	0.0%	1	-4.47	3	B
NTHINeonc Technologies Holdings, Inc.	$3.60	-2.56×	-9.07×	3,973.02×	-2.77×	-122.3%	100.0%	-145459.4%	-155404.4%	355.0%	519.7%	-13.1%	-0.36×	-0.1×	-23.23×	0.07×	0.0%	2	-66.25	2	C
OABIOmniAb, Inc.	$5.36	-3.25×	0.79×	11.26×	-4.6×	-105.3%	-18.2%	-383.1%	-347.0%	-24.3%	-24.2%	-17.6%	0.08×	0.12×	0×	4.02×	0.0%	4	9.56	2	C
OBIOOrchestra BioMed Holdings, Inc.	$5.70	-3.74×	3.13×	5.92×	-3.5×	-202.6%	99.4%	-154.7%	-157.4%	-83.2%	-52.4%	-25.0%	0.25×	0.37×	-45.13×	6.45×	0.0%	3	-2.89	1	D+
Peer median	—	-3.26×	1.76×	7.96×	-3.99×	-122.3%	93.0%	-154.7%	-157.4%	-24.3%	-24.2%	-16.8%	0.08×	0.12×	-7.96×	4.02×	0.0%	3	-4.47	2	—